Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478824 · ClinicalTrials.gov registry record
IL13 Signaling in Allergic Asthma
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 28
- Enrollment target
NCT05478824 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 28 participants.
The verdict
NCT05478824 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic and non-allergic patients with asthma and obesity and drive significant differential responses to dupilumab. It is further hypothesized that dupilumab will increase interleukin-13 receptor alpha 2 (IL-13Rα2) levels and/or signaling activity on airway epithelial cells isolated from allergic asthma patients with obesity. This is a pre-clinical research study of dupilumab-induced gene and protein expression analyses in nasal airway epithelial cells of adults with asthma and comorbid obesity. The study primarily seeks to: 1) assess the effect of dupilumab on transcriptomes, phosphoproteomes and secretomes of well-differentiated, primary airway epithelial cells as a function IL-13R subunit expression and IL-13Ra2 signaling, in allergic and non-allergic asthma patients with obesity; and 2) test whether dupilumab-induced gene and protein changes significantly correlate with parameters of airway inflammation in allergic and non-allergic asthma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2025-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478824
The ClinicalTrials.gov registry entry for NCT05478824 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05478824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05478824 about?
NCT05478824 is a clinical study titled "IL13 Signaling in Allergic Asthma". This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic and non-allergic patients with asthma and obesity and drive significant...
What is the current status of trial NCT05478824?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2023-02-21. Estimated completion is 2025-11-11.
Who is sponsoring clinical trial NCT05478824?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.